Guidance A-Z — Z
8 guidance documents beginning with Z.
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment
Zanubrutinib for treating chronic lymphocytic leukaemia
Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment
Zanubrutinib for treating relapsed or refractory mantle cell lymphoma
Zanubrutinib for treating Waldenstrom's macroglobulinaemia
Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal)
Zio XT for detecting cardiac arrhythmias
Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma
Zanubrutinib for treating chronic lymphocytic leukaemia
Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment
Zanubrutinib for treating relapsed or refractory mantle cell lymphoma
Zanubrutinib for treating Waldenstrom's macroglobulinaemia
Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal)
Zio XT for detecting cardiac arrhythmias
Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma
